Literature DB >> 22544673

Youngest survivor of naegleria meningitis.

Dinesh Yadav1, Satinder Aneja, Renu Dutta, Anu Maheshwari, Anju Seth.   

Abstract

Primary amebic meningoencephalitis (PAME) is a rare condition, usually caused by free living motile amebae. These are universally fatal infections with very few survivors reported till now. The authors report a 25-d-old boy, the youngest survivor of Naegleria meningitis. The child was admitted with a diagnosis of partially treated meningitis. Cerebro-spinal fluid wet mount examination revealed free living motile amebae resembling Naegleria, which was further confirmed by culture. He was treated with amphoterecin B, rifampicin and fluconazole for 4 wk and ventriculoperitoneal shunt for obstructive hydrocephalous. At 8 mo follow up, child has survived with neurological sequlae.

Entities:  

Mesh:

Year:  2012        PMID: 22544673     DOI: 10.1007/s12098-012-0756-2

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

1.  Naegleria meningitis.

Authors:  S N Singh; A K Patwari; R Dutta; N Taneja; V K Anand
Journal:  Indian Pediatr       Date:  1998-10       Impact factor: 1.411

2.  Fatal case of Naegleria fowleri meningo-encephalitis in an infant: case report.

Authors:  Shrikiran Hebbar; Indira Bairy; Nalini Bhaskaranand; Santhosh Upadhyaya; Moinak Sen Sarma; Anup Kumar Shetty
Journal:  Ann Trop Paediatr       Date:  2005-09

3.  Primary amebic meningoencephalitis.

Authors:  S L Tungikar; A G Kulkarni; A D Deshpande; V S Gosavi
Journal:  J Assoc Physicians India       Date:  2006-04

4.  Primary amoebic meningo-encephalitis in two Indian children.

Authors:  N R Pan; B C Roy; T N Ghosh
Journal:  J Indian Med Assoc       Date:  1971-03-01

5.  Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report.

Authors:  M Fowler; R F Carter
Journal:  Br Med J       Date:  1965-09-25

6.  Growth inhibition of Naegleria fowleri by tetracycline, rifamycin, and miconazole.

Authors:  Y H Thong; B Rowan-Kelly; C Shepherd; A Ferrante
Journal:  Lancet       Date:  1977-10-22       Impact factor: 79.321

7.  Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin.

Authors:  Jesús Vargas-Zepeda; Alejandro V Gómez-Alcalá; José Alfonso Vásquez-Morales; Leonardo Licea-Amaya; Johan F De Jonckheere; Fernando Lares-Villa
Journal:  Arch Med Res       Date:  2005 Jan-Feb       Impact factor: 2.235

8.  Primary meningoencephalitis by Naegleria fowleri: first reported case from Mangalore, South India.

Authors:  Shalini Shenoy; Godwin Wilson; H V Prashanth; K Vidyalakshmi; B Dhanashree; R Bharath
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

9.  Naegleria meningitis: a rare survival.

Authors:  R Jain; S Prabhakar; M Modi; R Bhatia; R Sehgal
Journal:  Neurol India       Date:  2002-12       Impact factor: 2.117

10.  Primary amebic meningoencephalitis.

Authors:  Ruchi Rai; D K Singh; A K Srivastava; Anudita Bhargava
Journal:  Indian Pediatr       Date:  2008-12       Impact factor: 1.411

  10 in total
  4 in total

1.  A case of primary amebic meningoencephalitis caused by Naegleria fowleri in Bangladesh.

Authors:  Hossain M S Sazzad; Stephen P Luby; James Sejvar; Mahmudur Rahman; Emily S Gurley; Vincent Hill; Jennifer L Murphy; Shantanu Roy; Jennifer R Cope; Ibne K M Ali
Journal:  Parasitol Res       Date:  2019-11-16       Impact factor: 2.289

2.  Naegleria fowleri after 50 years: is it a neglected pathogen?

Authors:  Moisés Martínez-Castillo; Roberto Cárdenas-Zúñiga; Daniel Coronado-Velázquez; Anjan Debnath; Jesús Serrano-Luna; Mineko Shibayama
Journal:  J Med Microbiol       Date:  2016-07-04       Impact factor: 2.472

3.  Prevalence of Naegleria fowleri in Environmental Samples from Northern Part of India.

Authors:  Ashutosh Panda; Shehla Khalil; Bijay Ranjan Mirdha; Yogita Singh; Samander Kaushik
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

Review 4.  Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae.

Authors:  Alexandre Taravaud; Zineb Fechtali-Moute; Philippe M Loiseau; Sébastien Pomel
Journal:  Clin Transl Sci       Date:  2021-03-01       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.